Adagrasib

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 321 publications

Opioid toxicity from impaired oxycodone metabolism associated with adagrasib.

Opioid toxicity from impaired oxycodone metabolism associated with adagrasib.

Journal: Clinical toxicology (Philadelphia, Pa.)

Published: June 15, 2026

Monoclonal antibodies targeting PCDH7 inhibit tumor growth and enhance immune responses in KRAS-mutant non-small cell lung cancer.

Monoclonal antibodies targeting PCDH7 inhibit tumor growth and enhance immune responses in KRAS-mutant non-small cell lung cancer.

Journal: Science advances

Published: June 03, 2026

Combining cutting edge computational and experimental methods for targeting KRAS mutations in non-small cell lung cancer.

Combining cutting edge computational and experimental methods for targeting KRAS mutations in non-small cell lung cancer.

Journal: Expert opinion on drug discovery

Published: April 20, 2026

Drug repurposing in KRAS G12C-mutant NSCLC: a focus on resistance mechanisms and clinical strategies.

Drug repurposing in KRAS G12C-mutant NSCLC: a focus on resistance mechanisms and clinical strategies.

Journal: Naunyn-Schmiedeberg's archives of pharmacology

Published: April 15, 2026

Pan-RAS Inhibitors: Expanding Therapeutic Potential and Evading Resistance.

Pan-RAS Inhibitors: Expanding Therapeutic Potential and Evading Resistance.

Journal: Cancers

Published: April 10, 2026

KRAS G12C-mutant non-small cell lung cancer: A practical guide for clinicians.

KRAS G12C-mutant non-small cell lung cancer: A practical guide for clinicians.

Journal: Cancer treatment reviews

Published: March 21, 2026

Discovery of Structurally Distinct Covalent KRAS G12C Inhibitor Scaffolds Through Large-Scale In Silico Screening and Experimental Validation.

Discovery of Structurally Distinct Covalent KRAS G12C Inhibitor Scaffolds Through Large-Scale In Silico Screening and Experimental Validation.

Journal: Cancers

Published: March 11, 2026

A Systematic Review of the Efficacy of KRAS p.G12C Inhibitors in Metastatic Colorectal Cancer: The Current State of Science.

A Systematic Review of the Efficacy of KRAS p.G12C Inhibitors in Metastatic Colorectal Cancer: The Current State of Science.

Journal: Cancer investigation

Published: March 05, 2026

From G12C To pan-RAS: The expanding therapeutic landscape of KRAS-mutant NSCLC.

From G12C To pan-RAS: The expanding therapeutic landscape of KRAS-mutant NSCLC.

Journal: Critical reviews in oncology/hematology

Published: January 28, 2026

Combining the KRASG12C inhibitor adagrasib with anti-PD-1 immunotherapy improves overall survival and prevents recurrence in preclinical models of brain metastasis.

Combining the KRASG12C inhibitor adagrasib with anti-PD-1 immunotherapy improves overall survival and prevents recurrence in preclinical models of brain metastasis.

Journal: Neuro-oncology advances

Published: January 27, 2026

MicroRNA Mimics Based on the miR-15/107 Consensus Sequence Sensitise NSCLC Cells to Targeted Therapy.

MicroRNA Mimics Based on the miR-15/107 Consensus Sequence Sensitise NSCLC Cells to Targeted Therapy.

Journal: International journal of molecular sciences

Published: January 22, 2026

PDK1 and YAP1/TEAD signaling drive acquired KRAS inhibitor resistance in KRAS-mutant non-small cell lung cancer.

PDK1 and YAP1/TEAD signaling drive acquired KRAS inhibitor resistance in KRAS-mutant non-small cell lung cancer.

Journal: bioRxiv : the preprint server for biology

Published: January 09, 2026

Showing 1-12 of 321

Last Updated: 06/30/2026